Julie R. Brahmer

2 weeks ago | onclive.com | Estelamari Rodriguez |Tarek Mekhail |Balazs Halmos |Susan Scott |Julie R. Brahmer |Corey J Langer | +1 more

CommentaryVideoApril 30, 2025Author(s):,Fact checked by:,Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Feb 20, 2024 | healio.com | Josh Friedman |Mindy Valcarcel |Julie R. Brahmer

You've successfully added Hematology Oncology: Lung Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Oct 3, 2023 | onclive.com | Julie R. Brahmer

Julie Renee Brahmer, MD, co-director, Upper Aerodigestive Department, the Bloomberg-Kimmel Institute for Cancer Immunotherapy, professor, oncology, Johns Hopkins Medicine, discusses the investigation of FLX475 in patients with advanced non–small cell lung cancer (NSCLC).